Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $424.06, for a total transaction of $1,696,240.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $55,127.80. The trade was a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Trading Down 1.4%

Shares of UTHR opened at $415.34 on Wednesday. The company has a market cap of $18.74 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 4.59 and a beta of 0.66. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $459.48. The company’s fifty day simple moving average is $401.57 and its 200 day simple moving average is $334.83.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 earnings per share. United Therapeutics’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UTHR. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics during the first quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on UTHR. Royal Bank Of Canada began coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an “outperform” rating and a $569.00 price objective on the stock. Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday, September 10th. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Finally, Jefferies Financial Group boosted their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $461.62.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.